Table 2 Patient characteristics... | American Society of Hematology

Table 2

Patient characteristics

Participant no.	Disease type	Disease status	Lymphocyte counts, K/μL	CD20 level on B cells, MCF	CD22 level on B cells, MCF	Binding of ^BPCNeuAc liposomes*
N-001	Normal	NA	2.5	1185	1739	++
N-002	Normal	NA	1.8	958	1708	++
N-003	Normal	NA	2.1	1226	1126	++
N-004	Normal	NA	1.6	1086	1137	++
B-001†	HCL	Remission	3.1	2471	1208	+++
B-003	HCL	Stable	0.9	3017	1665	+++
B-005	HCL	Untreated	1.1	8613	6128	++++
B-009	HCL	Untreated	1.1	1202	2971	++++
B-017	HCL	Progression	0.9	154	1651	+++
B-018	HCL	Relapsed	14.1	327	1035	+++
B-021†	HCL	Remission	1.8	95	6445	++++
B-022	HCL	Relapsed	1.8	219	3322	++++
B-002	CLL	Stable	23	418	324	+
B-006	CLL	Progression	97.7	271	217	+
B-007	CLL	Progression	36.4	1476	359	+
B-008†	CLL	Stable	54.3	232	50	+/−
B-013	CLL	Untreated	50.1	150	219	+
B-015†	CLL	Stable	171	329	39	+/−
B-016	CLL	Progression	70.5	67	192	+
B-020	CLL	Progression	47.3	41	66	+
B-023	CLL	Untreated	27.1	55	63	+/−
B-024	CLL	Untreated	15.3	41	202	+
B-025	CLL	Untreated	81.4	45	268	+/−
B-027	CLL	Untreated	58.3	56	235	+
B-029†	CLL	Progression	78.8	42	56	+/−
B-030†	CLL	Progression	130	54	351	+
B-004	MZL	Progression	80	1274	2246	+++
B-010	MZL	Progression	34.3	1219	2157	+++
B-011	MZL	Stable	22.8	564	838	++
B-012†	MZL	Progression	97.8	421	1190	+++
B-014†	MZL	Progression	74.9	587	750	++
B-019	MZL	Untreated	54	176	1648	+++
B-026	MZL	Progression	10.1	987	1126	+++
B-028	MZL	Untreated	1.1	536	1098	+++

Participant no.	Disease type	Disease status	Lymphocyte counts, K/μL	CD20 level on B cells, MCF	CD22 level on B cells, MCF	Binding of ^BPCNeuAc liposomes*
N-001	Normal	NA	2.5	1185	1739	++
N-002	Normal	NA	1.8	958	1708	++
N-003	Normal	NA	2.1	1226	1126	++
N-004	Normal	NA	1.6	1086	1137	++
B-001†	HCL	Remission	3.1	2471	1208	+++
B-003	HCL	Stable	0.9	3017	1665	+++
B-005	HCL	Untreated	1.1	8613	6128	++++
B-009	HCL	Untreated	1.1	1202	2971	++++
B-017	HCL	Progression	0.9	154	1651	+++
B-018	HCL	Relapsed	14.1	327	1035	+++
B-021†	HCL	Remission	1.8	95	6445	++++
B-022	HCL	Relapsed	1.8	219	3322	++++
B-002	CLL	Stable	23	418	324	+
B-006	CLL	Progression	97.7	271	217	+
B-007	CLL	Progression	36.4	1476	359	+
B-008†	CLL	Stable	54.3	232	50	+/−
B-013	CLL	Untreated	50.1	150	219	+
B-015†	CLL	Stable	171	329	39	+/−
B-016	CLL	Progression	70.5	67	192	+
B-020	CLL	Progression	47.3	41	66	+
B-023	CLL	Untreated	27.1	55	63	+/−
B-024	CLL	Untreated	15.3	41	202	+
B-025	CLL	Untreated	81.4	45	268	+/−
B-027	CLL	Untreated	58.3	56	235	+
B-029†	CLL	Progression	78.8	42	56	+/−
B-030†	CLL	Progression	130	54	351	+
B-004	MZL	Progression	80	1274	2246	+++
B-010	MZL	Progression	34.3	1219	2157	+++
B-011	MZL	Stable	22.8	564	838	++
B-012†	MZL	Progression	97.8	421	1190	+++
B-014†	MZL	Progression	74.9	587	750	++
B-019	MZL	Untreated	54	176	1648	+++
B-026	MZL	Progression	10.1	987	1126	+++
B-028	MZL	Untreated	1.1	536	1098	+++

MCF indicates mean channel fluorescence of malignant B lymphocytes; HCL, hairy cell leukemia; CLL, chronic lymphocytic leukemia; MZL, marginal zone lymphoma; and NA, not applicable.

Binding of ^BPCNeuAc liposomes to B cells was determined as MCF intensity: ++++ indicates MCF > 500; +++, 500 > MCF > 100; ++, 100 > MCF > 50; +, 50 > MCF > 10; and +/−, MCF < 10.

†

Patients previously treated with rituximab.

View Large

This Feature Is Available To Subscribers Only